Intratio
Loading...
Skip to main content
Model output · Signal date 2026-10-15

Oruka Therapeutics, Inc. (ORKA) Stock Forecast Oct. 15, 2026

Analysis updated on Oct. 15, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq

Follow Unlock full AI forecasts
Rating · 90D ▲ Bullish Exact rating locked
90-day forecast Sign up free to reveal
30-day forecast Alpha
Rank in coverage Top 35% of 5111 stocks scored
Rank correlation · 90D 49.0% Spearman, 358 dates
Market Cap $5.08B mid-cap · #54 of 60 peers
Summary

Oruka Therapeutics, Inc. (ORKA) stock forecast summary

Our AI ranks Oruka Therapeutics, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.

Oruka Therapeutics, Inc. is a mid-cap company with a market capitalization of $5.08B. It ranks number 54 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast.

For ORKA, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 49.0%, measured on 358 forecast dates between 2022-07-28 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 32.0%, measured on 400 forecast dates between 2022-07-28 and 2026-09-15. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.5% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-15 signals)

A free account shows the exact forecast, rating and rank of 3 tickers you follow, ORKA included.

Follow ORKA free
Price

ORKA price chart and AI forecast

ORKA
Cross-section · 2026-10-15

How ORKA ranks among 5111 stocks

90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).

Fundamentals · 2026-06-30

Oruka Therapeutics, Inc. (ORKA) fundamentals

Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric.

Valuation & Market

MetricORKAIndustry medianRank
Market Cap $5.08B $12.63B 54/60
P/B Ratio 4.56x 7.46x 31/40
EPS $-4.15 – –
Book Value/Share $16.83 – –
FCF/Share $-1.53 – –

Profitability & Margins

MetricORKAIndustry medianRank
ROIC -13.9% 1.2% 29/44

Financial Health

MetricORKAIndustry medianRank
Current Ratio 38.51x 2.96x 3/56
D/E Ratio 0.02x 1.26x 43/45
Financial Leverage 1.02x 2.12x 43/45
Interest Coverage -15.9x 1.0x 25/35
Working Capital $862M $945M 30/56

Cash Flow

MetricORKAIndustry medianRank
Operating Cash Flow -$101M $183M 41/56
Free Cash Flow -$101M $164M 34/47
Capital Spending -$230K -$64M 2/47

Income Statement

MetricORKAIndustry medianRank
Operating Income -$155M $76M 30/48
R&D Expense $129M $548M 50/55

Dividend & Shareholder Information

MetricORKAIndustry medianRank
Shares Outstanding 66M – –

Balance Sheet Highlights (USD millions)

Total Current Assets$885M77.7% of assets
Cash & Short-term Investments$268M23.6% of assets
Total Liabilities$25M2.2% of assets
Quarterly Financial Reports

ORKA quarterly financials and insider trading

Industry Peers · Pharmaceutical Preparations

Oruka Therapeutics, Inc. (ORKA) industry peers

Companies classified under the same SEC industry code as Oruka Therapeutics, Inc. (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.

Reveal all forecasts · See exact % predictions for all competitors

Sign up free
Company 90-Day AI Forecast (Alpha) Market Cap P/E Ratio P/B Ratio
ORKA Oruka Therapeutics, Inc. ▲ $5.08B – 4.6x
LLY Eli Lilly & Co ▶ $1.14T 40.6x 115.8x
JNJ Johnson & Johnson ▼ $611.90B 29.5x 7.2x
ABBV Abbvie Inc. ▶ $500.75B 73.2x –
MRK Merck & Co., Inc. ▶ $363.59B 117.9x 8.7x
NVS Novartis Ag ▼ $280.27B 8.8x –
AZN Astrazeneca Plc ▼ $251.15B 11.7x –
ABT Abbott Laboratories ▼ $182.04B 29.3x 3.5x
NVO Novo Nordisk A S ▼ $169.41B 2.8x –
PFE Pfizer Inc ▼ $166.49B 36.1x 2.0x
VRTX Vertex Pharmaceuticals Inc / Ma ▼ $126.35B 28.7x 6.2x
BMY Bristol Myers Squibb Co ▶ $121.09B 13.0x 5.4x
SNY Sanofi ▼ $98.05B – –
GSK Gsk Plc ▼ $96.58B 5.3x –
REGN Regeneron Pharmaceuticals, Inc. ▶ $80.48B 19.3x 2.5x
TEVA Teva Pharmaceutical Industries Ltd ▶ $47.45B 67.1x 6.1x
ONC Beone Medicines Ltd. ▲ $39.96B 1212.0x 7.7x
RPRX Royalty Pharma Plc ▲ $33.92B 41.6x 5.0x
ZTS Zoetis Inc. ▼ $31.11B 11.9x 9.9x
TAK Takeda Pharmaceutical Co Ltd ▶ $30.24B – –
ALNY Alnylam Pharmaceuticals, Inc. ▲ $30.04B 56.4x 22.2x
ATHE Alterity Therapeutics Ltd ▶ $25.65B – –
ZLAB Zai Lab Ltd ▶ $25.26B – 41.6x
ROIV Roivant Sciences Ltd. ▲ $24.28B – 5.7x
GMAB Genmab A/S ▶ $23.73B 1.5x –
UTHR United Therapeutics Corp ▼ $23.16B 17.7x 3.6x
INSM Insmed Inc ▶ $21.36B – 28.2x
VTRS Viatris Inc ▶ $20.03B – –
ASND Ascendis Pharma A/S ▲ $14.97B – –
JAZZ Jazz Pharmaceuticals Plc ▼ $13.61B 14.3x 2.8x
BBIO Bridgebio Pharma, Inc. ▶ $12.69B – –
CORT Corcept Therapeutics Inc ▲ $12.56B 130.6x 17.8x
SMMT Summit Therapeutics Inc. ▶ $12.07B – 19.2x
ELAN Elanco Animal Health Inc ▼ $11.27B – 1.7x
BMRN Biomarin Pharmaceutical Inc ▶ $10.67B 68.9x 1.7x
RDY Dr Reddys Laboratories Ltd ▼ $10.64B 14.0x –
MDGL Madrigal Pharmaceuticals, Inc. ▶ $10.63B – 20.3x
PTGX Protagonist Therapeutics, Inc ▶ $8.82B 172.5x 10.5x
CYTK Cytokinetics Inc ▲ $8.82B – –
AXSM Axsome Therapeutics, Inc. ▲ $8.50B – 102.0x
ARWR Arrowhead Pharmaceuticals, Inc. ▲ $8.25B – 17.7x
ABVX Abivax S.A. ▼ $7.26B – –
IONS Ionis Pharmaceuticals Inc ▲ $7.10B – 16.1x
SYRE Spyre Therapeutics, Inc. ▲ $6.93B – 6.3x
PRAX Praxis Precision Medicines, Inc. ▲ $6.67B – 5.0x
ALKS Alkermes Plc. ▲ $6.56B 43.0x 3.6x
KNSA Kiniksa Pharmaceuticals International, Plc ▼ $6.16B 86.6x 10.2x
AMRX Amneal Pharmaceuticals, Inc. ▲ $6.04B 57.3x –
BLTE Belite Bio, Inc ▲ $6.01B – 7.8x
RYTM Rhythm Pharmaceuticals, Inc. ▶ $5.97B – 58.0x
LGND Ligand Pharmaceuticals Inc ▶ $5.88B 28.6x 6.1x
BLRX Biolinerx Ltd. ▶ $5.43B – –
MIRM Mirum Pharmaceuticals, Inc. ▲ $5.19B – –
ERAS Erasca, Inc. ▲ $5.14B – 14.2x
TVTX Travere Therapeutics, Inc. ▲ $5.02B – 204.8x
PTCT Ptc Therapeutics, Inc. ▲ $4.98B – –
COGT Cogent Biosciences, Inc. ▶ $4.88B – 9.2x
MANE Veradermics, Inc ▲ $4.74B – 5.8x
DNTH Dianthus Therapeutics, Inc. /De/ ▲ $4.18B – 3.6x
INDV Indivior Pharmaceuticals, Inc. ▼ $4.03B 13.8x –

Where ORKA sits on the market map

Life Sciences · Pharmaceutical Preparations
Explore the map →
News

Oruka Therapeutics, Inc. (ORKA) stock news

Loading...

FAQ

Oruka Therapeutics, Inc. (ORKA) stock forecast FAQ

What is the Oruka Therapeutics, Inc. (ORKA) stock forecast?

Our AI ranks Oruka Therapeutics, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.

How accurate are Oruka Therapeutics, Inc. stock predictions?

For ORKA, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 49.0%, measured on 358 forecast dates between 2022-07-28 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 32.0%, measured on 400 forecast dates between 2022-07-28 and 2026-09-15. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

How often are Oruka Therapeutics, Inc. forecasts updated?

Oruka Therapeutics, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 15, 2026.

Which companies are Oruka Therapeutics, Inc.'s industry peers?

60 issuers in our coverage, ORKA included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS), Astrazeneca Plc (AZN).

This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.